Ziad Bakouny, MD, MSc

home / authors / ziad-bakouny-md-msc

Articles

Dr. Bakouny on Understanding the Biology of Translocation RCC

January 19th 2022

Ziad Bakouny, MD, MSc, discusses understanding the biology of translocation renal cell carcinoma.

Dr. Bakouny on the Rate of Disease Progression in Sarcomatoid Carcinoma

Ziad Bakouny, MD, MSc

October 12th 2020

Ziad Bakouny, MD, MSc, discusses the rate of disease progression in sarcomatoid carcinoma.

Dr. Bakouny on the Utility of Checkpoint Inhibitors in Sarcomatoid RCC

Ziad Bakouny, MD, MSc

April 2nd 2020

Ziad Bakouny, MD, MSc, discusses the utility of checkpoint inhibitors in renal cell carcinoma with sarcomatoid differentiation.

Dr. Bakouny on the Role of Cytoreductive Nephrectomy in mRCC

Ziad Bakouny, MD, MSc

February 19th 2020

Ziad Bakouny, MD, MSc, discusses the role of cytoreductive nephrectomy in metastatic renal cell carcinoma.

New Perioperative Strategies Emerge for High-Risk, Resectable RCC

Ziad Bakouny, MD, MSc;Ronan Flippot, MD, MSc;David A. Braun, MD, PhD;Lauren C. Harshman, MD;Toni K. Choueiri, MD

December 4th 2019

The current management of metastatic renal cell carcinoma reflects the progress of medical oncology throughout the past several decades. The standard of care has evolved from cytokine-based therapies to targeted molecular therapies and immune checkpoint inhibitor–based strategies.

Investigators Seek Expanded Use of Checkpoint Inhibitors in RCC

Ziad Bakouny, MD, MSc;Bradley A. McGregor, MD;Toni K. Choueiri, MD

December 5th 2018

In contrast to the wide array of available therapies in the metastatic setting of renal cell carcinoma, in patients with localized disease, the results of trials investigating adjuvant systemic therapy after nephrectomy have so far been underwhelming.